Introduction
============

In the adult brain, new functional neurons are generated from neural stem/progenitor cells (NSPC), which have the ability to self-renew their own pool through cell proliferation and/or to generate cells of the neural lineage (neurons, astrocytes and oligodendrocytes) ([@B28]; [@B37]). This process, so called neurogenesis, occurs mainly in two restricted areas, the SVZ lining the lateral ventricles, and the SGZ within the DG of the hippocampus. In fact, SVZ and SGZ are regions rich in NSPC that originate neuroblasts, which then migrate toward their final destinations where they differentiate into mature neurons, a few being integrated into the neuronal circuitry ([@B46]; [@B75]; [@B53]).

These neurogenic niches are highly regulated by several factors that dictate the NSPC rates of proliferation, differentiation, survival and maturation ([@B53]). These factors play a crucial regulatory role under neuropathological conditions, in an attempt to balance the system, favoring the correct incorporation of newly formed neurons into the circuitry ([@B74]). Therefore, understanding the molecular mechanisms and key elements that control the maintenance of neurogenic niches will contribute to the development of future potential therapies for brain disorders.

In recent years, an increasing interest has emerged on the role of endocannabinoids in neurogenesis. Cannabinoids act mainly on two types of receptors, type 1 and type 2 cannabinoid receptors (CB~1~R and CB~2~R). CB~1~R is considered the neuronal receptor whereas CB~2~R is considered the receptor of the immune system ([@B29]), although increasing evidence shows that CB~2~R is present in several neuronal cell types ([@B58]; [@B67]). CB~1~R and CB~2~R are G-protein coupled receptors (GPCRs) predominantly targeted by anandamide (AEA) and 2-arachidonylglycerol (2-AG), the two major endocannabinoids in the CNS. These molecules target cannabinoid receptors differently: 2-AG acts as a full agonist of CB~1~R and CB~2~R whereas AEA acts a partial agonist for CB~1~R and CB~2~R ([@B47]). AEA and 2-AG are generated by the cleavage of membrane lipid precursors upon neural activity (on-demand synthesis model) ([@B57]), and act as fast retrograde messengers to activate CB~1~R in presynaptic terminals and inhibit neurotransmitter release ([@B14]; [@B51]). Doing so, cannabinoid receptors regulate neurocircuitry dynamics, thus having important roles in many pathological processes such as anxiety, depression, feeding behavior, Parkinson's disease, Alzheimer's disease, neuroinflammation and pain ([@B44]; [@B43]; [@B19]).

Besides their neuromodulatory role, endocannabinoids constitute a group of signaling cues that can regulate neurogenesis at several levels, including NSPC proliferation, differentiation, migration and survival, these actions being associated to either CB~1~R or CB~2~R ([@B3]; [@B63]). In fact, CB~1~Rs and CB~2~Rs were shown to be expressed in rat SVZ and DG tissue and neurosphere-derived cells ([@B55]; [@B34]; [@B7]). Importantly, CB~1~R activation was shown to promote proliferation in embryonic cultures, in SVZ neurosphere cultures and in the DG of 6-week old mice ([@B5]; [@B40]; [@B6]). In the same way, activation of CB~1~R was also found to induce differentiation and maturation of *in vitro* NSPC ([@B15]; [@B73]). Moreover, gathering evidence shows the implication of CB~2~R in processes related to the control of proliferation, differentiation, migration and survival of NSPC. Activation of CB~2~R was, indeed, shown to promote proliferation in embryonic cell lines, in SVZ neurosphere cultures and in the SVZ of young mice, as well as differentiation of human NSPC ([@B59], [@B60]; [@B33]; [@B8]; [@B21]). Interestingly, it was recently shown that CB~2~R is necessary for neuroblast migration after stroke ([@B12]).

Cannabinoid-based therapy may constitute a novel therapeutic strategy in the emerging field of brain repair. Indeed, some symptoms associated with adult brain disorders appear to be correlated with dysregulation of endocannabinoid signaling ([@B29]; [@B51]). Of particular interest, CB~2~R play an important role in neuro-immunomodulatory responses and, unlike CB~1~R, do not produce any psychoactive effects, thus being particularly promising targets to treat neuroinflammation-related brain disorders ([@B22]; [@B65]).

Increasing evidence point to an important role of interactions between GCPR in the CNS, as well as to heteroreceptor formation ([@B26], [@B25]; [@B35]; [@B23]). In fact, CB~1~R were shown to modulate the release of several neuromodulators including dopamine, opioids, norepinephrine and others by interacting with other GPCRs, either by intracellular crosstalk of signal transduction or by forming heterodimers ([@B48]; [@B18]; [@B56]; [@B27]; [@B14]). Similarly, crosstalk between CB~2~R and other GPCRs is also known to occur although the molecular and cellular basis for these interactions, the extent to which they occur and the impact on CNS function is still not fully understood ([@B13]; [@B9]; [@B49]). Importantly, molecular and functional heteromerization of CB~1~R and CB~2~R has been shown for the first time in the study of [@B13], where they demonstrated the presence of CB~1~R-CB~2~R heteromers in a variety of brain regions, depicting the existence of a bidirectional cross-antagonism phenomenon. Functional consequences of this heteromerization are poorly known.

Given the evidence that both CB~1~R and CB~2~R can affect neurogenesis as well as the evidence that CB~1~R and CB~2~R receptors may interact, we hypothesized that both receptors could act together to fine-tune neurogenesis. By testing this hypothesis, we now show for the first time that the action of cannabinoids on proliferation and differentiation of SVZ and DG NSPC involves a close interaction between CB~1~R and CB~2~R, suggesting a fundamental role of this crosstalk in the modulation of postnatal neurogenesis.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

This study was carried out in accordance with the recommendations of "Directive 2010/63/EU." The protocol was approved by the "iMM's institutional Animal Welfare Body -- ORBEA-iMM and the National competent authority -- DGAV (Direcção Geral de Alimentação e Veterinária)."

SVZ and DG Cell Cultures
------------------------

SVZ and DG neurospheres were prepared from early postnatal (P1-3) Sprague-Dawley rats. SVZ and DG fragments were dissected out from 450 μm-thick coronal brain slices, digested with 0.05% Trypsin-EDTA (Life Technologies, Carlsbad, CA, United States) in Hank's balanced saline solution (HBSS, Life Technologies), and mechanically dissociated with a P1000 pipette. The originated cell suspension was then diluted in serum-free medium (SFM), composed of Dulbecco's modified Eagle's medium/Ham's F-12 medium with GlutaMAX (DMEM + GlutaMAX, Life Technologies) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (Pen/Strep; Life Technologies), 1% B27 (Life Technologies) and growth factors (for SVZ cells: 20 ng/mL EGF; Life Technologies); for DG cells: 20 ng/mL EGF (Life Technologies) and 10 ng/mL FGF-2 (Life Technologies) (proliferative conditions). Single cells were then plated on uncoated Petri dishes at a density of 5,000 cells per cm^2^. SVZ cells were allowed to develop for six days, whereas DG cells were allowed to develop for twelve days, both in a 95% air-5% CO~2~ humified atmosphere at 37°C. Rat SVZ and DG neurospheres require different culture conditions, time length and growth factors, because DG-derived neurospheres need more time to reach optimal dimensions when comparing with SVZ ([@B38]) and SVZ cells do not require the growth factor FGF-2 to expand into neurospheres ([@B61]; [@B45]; [@B72]). Six-day-old SVZ neurospheres and 12-day-old DG neurospheres were adhered for 24 h onto glass coverslips (at a density of approximately 60 neurospheres per well) coated with 0.1 mg/mL poly-[D]{.smallcaps}-lysine (PDL, Sigma--Aldrich, St. Louis, MO, United States) in SFM devoid of growth factors (differentiative conditions). One day after plating, the medium was renewed with or without (control) a range of pharmacological treatments for CB~1~R and CB~2~R ligands, chosen based on their affinity for CB~1~R and CB~2~R represented by *K~i~* value (**Table [1](#T1){ref-type="table"}**).

###### 

Pharmacological treatments used.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                                                                          Biological activity                                         Concentration used   *K~i~* value, nM (according to [@B62])              Catalog number   Company
  ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- -------------------- --------------------------------------------------- ---------------- ---------------------------------
  **WIN55,212-2**\                                                                                                              Cannabinoid receptor CB~1~ or CB~2~ non-selective agonist   100 nM\              1.89 to 123 for CB~1~R or 0.28 to 16.2 for CB~2~R   1038             Tocris, Bristol, United Kingdom
  \[(R)-(+)-\[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo\[1,2,3-de\]-1,4-benzoxazin-6-yl\]-1-naphthalenylmethanone\]                                                               300 nM\                                                                                   
                                                                                                                                                                                            1 μM                                                                                      

  **ACEA**\                                                                                                                     Cannabinoid CB~1~ receptor selective agonist                100 nM\              1.4 for CB~1~R                                      1319             
  \[*N*-(2-Chloroethyl)-5*Z*,8*Z*,11*Z*,14*Z*-eicosatetraenamide\]                                                                                                                          300 nM\                                                                                   
                                                                                                                                                                                            1 μM                                                                                      

  **HU-308**\                                                                                                                   Cannabinoid CB~2~ receptor selective agonist                100 nM\              22.7 for CB~2~R                                     3088             
  \[4-\[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl\]-6,6-dimethylbicyclo\[3.1.1\]hept-2-ene-2-methanol\]                                                                                    300 nM\                                                                                   
                                                                                                                                                                                            1 μM                                                                                      

  **AM251**\                                                                                                                    Cannabinoid CB~1~ receptor selective antagonist             1 μM                 7.49 for CB~1~R                                     1117             
  \[*N*-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H-*pyrazole-3-carboxamide\]                                                                                                                                                                               

  **AM630**\                                                                                                                    Cannabinoid CB~2~ receptor selective antagonist             1 μM                 31.2 for CB~2~R                                     1120             
  \[6-Iodo-2-methyl-1-\[2-(4-morpholinyl)ethyl\]-1*H*-indol-3-yl\](4-methoxyphenyl)methanone\]                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pharmacological Treatments
--------------------------

To study cell proliferation, plated neurospheres were allowed to develop for 24 h (DIV 1) in the absence (control) or presence of CB~1~R and/or CB~2~R ligands (**Table [1](#T1){ref-type="table"}**). Neuronal differentiation was assessed by allowing neurospheres to develop for 7 days (DIV 7) in the absence (control) or presence of the aforementioned ligands and an immunocytochemistry for different neuronal markers was performed. To study neuritogenesis, SVZ and DG neurospheres were dissociated using phosphate-buffered saline (PBS) without Mg^2+^/Ca^2+^ and with EDTA (2.5 mM KCl, 1.5 mM KH~2~PO~4~, 135 mM NaCl, 8 mM Na~2~HPO~4~, 0.5 mM EDTA.4Na) and plated in differentiative conditions at a density of 10000 cell/cm^2^. DG and SVZ cells were allowed to grow for 2 (DIV 2) and 3 days (DIV 3), respectively, in the absence (control) or presence of the aforementioned ligands and were then fixed and stained for βIII tubulin (neuron-specific class III beta-tubulin).

Whenever cultures needed to be co-treated with both agonists, SVZ or DG cells were primarily treated with CB~1~R (ACEA) selective agonist for 30 min prior to CB~2~R selective agonist (HU-308) treatment and then grown for 24 h or 7 days in the presence of the ligands (**Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}**). Similarly, treatment with the selective antagonist for CB~1~R (AM251) or CB~2~R (AM630) was performed for 30 min prior to the treatment with the non-selective cannabinoid receptor agonist WIN55,212-2 or CB~1~R (ACEA) or CB~2~R (HU-308) selective agonists and then co-incubated for further 24 h or 7 days (**Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}**). Additionally, whenever cultures needed to be treated with a combination of both antagonists and both agonists, SVZ and DG cells were firstly treated with selective antagonists for CB~1~R (AM251) and CB~2~R (AM630) for 30 min prior to CB~1~R selective agonist (ACEA), incubated for further 30 min before CB~2~R selective agonist (HU-308) treatment. Thereafter cells were allowed to grow for 24 h in the case of cell proliferation studies or 7 days in the case of neuronal differentiation studies (**Supplementary Figure [S1C](#SM1){ref-type="supplementary-material"}**).

Cell Proliferation Study
------------------------

To investigate the effect of the different pharmacological treatments on cell proliferation, SVZ and DG cells were exposed to 10 μM 5-bromo-2′-deoxyuridine (BrdU) (Sigma--Aldrich) for the last 4 h of each specific pharmacological treatment (24 h, DIV1). BrdU is a synthetic thymidine analog able to substitute thymidine in the DNA double chain synthesis occurring in dividing cells. Furthermore, neuronal differentiation of proliferating progenitors was assessed in SVZ and DG cells that were incubated in the absence (control) or in the presence of CB~1~R/CB~2~R ligands together with 10 μM BrdU for 24 h. Then the cells were washed and incubated without BrdU for more 6 days, fixed and co-stained for BrdU and a marker of mature neurons (neuronal nuclear protein, NeuN). For that, SVZ and DG cells were fixed in 4% paraformaldehyde (PFA), BrdU was unmasked by permeabilizing cells in PBS 1% Triton X-100 (Sigma--Aldrich) and DNA was denaturated in 1M HCl. Following blocking in PBS with 0.5% Triton X-100 and 3% bovine serum albumin (BSA), cells were incubated overnight with the anti-BrdU antibody and anti-NeuN antibodies (**Table [2](#T2){ref-type="table"}**). Cells were incubated with the secondary anti-rat Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 (**Table [2](#T2){ref-type="table"}**). Nuclei were stained with Hoechst 33342 (6 μg/mL in PBS, Life Technologies). The final preparations were mounted using Mowiol fluorescent medium.

###### 

Antibodies used for immunocytochemistry.

  Antigen                                           Company                                                      Catalog number   Host         Dilution
  ------------------------------------------------- ------------------------------------------------------------ ---------------- ------------ ----------
  **Primary antibodies**                                                                                                                       
  βIII tubulin                                      Cell Signaling Technology                                    4466             Mouse        1:500
  BrdU (5-bromo-2'-deoxyuridine)                    AbD Serotec, Bio-Rad Laboratories (Oxford, United Kingdom)   OBT00306         Rat          1:200
  CB~1~R (Cannabinoid receptor type 1)              Frontier Institute Co., Ltd (Japan)                          CB1-GP-Af530     Guinea Pig   1:200
  CB~2~R (Cannabinoid receptor type 2)              Santa Cruz Biotechnology                                     sc-293188        Mouse        1:200
  Doublecortin (DCX)                                Santa Cruz Biotechnology                                     sc-8066          Goat         1:200
  Neuronal Nuclei (NeuN) (mature neuronal marker)   Cell Signaling Technology (Danvers, MA, United States)       12943            Rabbit       1:100
  Nestin                                            Abcam (Cambridge, United Kingdom) Invitrogen                 ab6142           Mouse        1:200
  Vesicular GABA Transporter (VGAT)                 Santa Cruz Biotechnology                                     sc-49574         Goat         1:200
  Vesicular Glutamate transporter 1 (VGluT1)        Synaptic Systems                                             135302           Rabbit       1:100
  Tyrosine Hydroxylase (TH)                         Immunostar                                                   22941            Mouse        1:100
  Sox2                                              Merk Millipore (Massachusetts, EUA)                          AB5603           Rabbit       1:200
  **Secondary antibodies**                                                                                                                     
  Anti-Goat Alexa Fluor^®^ 488                      Thermo Fisher Scientific (Rockford, IL, United States)       A-11055          Donkey       1:200
  Anti-Rat Alexa Fluor^®^ 488                       Thermo Fisher Scientific (Rockford, IL, United States)       A-21208          Donkey       1:200
  Anti-Rabbit Alexa Fluor^®^ 568                    Thermo Fisher Scientific (Rockford, IL, United States)       A-10042          Donkey       1:200
  Anti-Goat Alexa Fluor^®^ 568                      Thermo Fisher Scientific (Rockford, IL, United States)       A-11057          Donkey       1:200
  Anti-Mouse Alexa Fluor^®^ 647                     Thermo Fisher Scientific (Rockford, IL, United States)       A-21235          Goat         1:200

Cell Differentiation Study
--------------------------

SVZ and DG cells treated for 7 days (DIV 7) were fixed in 4% PFA, permeabilized and blocked with 0.5% Triton X-100 and 6% BSA in PBS. Cells were then incubated overnight at 4°C with the primary antibodies against different neuronal markers in 0.1% Triton X-100 and 0.3% BSA (w/v) in PBS, and then with the appropriate secondary antibodies in PBS (**Table [2](#T2){ref-type="table"}**). Nuclei counterstaining and mounting were performed as described previously.

Western Immunobloting Analysis and Co-immunoprecipitation
---------------------------------------------------------

Western blotting analysis of CB~1~R and CB~2~R was performed using SVZ and DG neurospheres that were plated and allowed to develop for 24 h (representing DIV 1) or 7 days (representing DIV 7) in SFM devoid of growth factors. The cells were harvested in RIPA lysis buffer \[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM ethylenediamine, tetra-acetic acid (EDTA), 0.1%SDS and 1%Triton X-100, containing a protease inhibitor cocktail (pH 7.4, 4°C, Roche, Penzberg, Germany)\]. Protein concentration was measured by the Lowry method and samples were treated with SDS-PAGE sample buffer \[5x concentrated: 350 mM Tris, 10% (w/v) SDS, 30% (v/v) glycerol, 0.6M DTT, 0.012% (w/v) bromophenol blue\], boiled 5 min at 95°C and processed for Western blotting analysis. All samples were applied with same amount of total protein and protein running was performed in SDS-PAGE gels (10% acrylamide/bisacrylamide for resolving and 5% for stacking gels), transferred to polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Buckinghamshire, United Kingdom). Incubations with the primary antibodies against CB~1~R (1:500, Frontier Institute Co., Ltd, Japan) and CB~2~R (1:1000, Santa Cruz Biotechnology) were performed overnight at 4°C. Membranes were incubated with the respective secondary antibodies: goat IgG anti-guinea pig and goat IgG anti-mouse conjugated with horseradish peroxidase (HRP) (1:10000; Santa Cruz Biotechnology). For endogenous control of immunolabeling, PVDF membranes were reprobed with the antibody against actin (1:1000; \#A2006, Sigma--Aldrich). Finally, immunoreactivity was visualized using ECL chemiluminescence detection system (Amersham-ECL Western Blotting Detection Reagents from GE Healthcare, Buckinghamshire, United Kingdom).

CB~2~Rs were immunoprecipitated from culture lysates using an antibody-bead mixture previously prepared. Rec-Protein *G*-Sepharose 4B Conjugate beads (Thermo Fisher Scientific) were first incubated with PBS 0.1% BSA for 1h at 4°C. After washing with PBS and centrifugation at 5000 rpm for 3 min, the pellet composed of beads was incubated for 4 h, at 4°C, with 1 μg of CB~2~R antibody. Following several washes, 35 μL of antibody-bead mixture was incubated with 250 μg of total protein (approximately 400 μL of culture lysate) overnight at 4°C. The mixture was centrifuged and the supernatant was collected. The remaining pellet of beads was washed three times with PBS 0.01% Tween 20 and re-suspended and denatured in 35 μL of SDS-PAGE sample buffer. Samples were boiled for 5 min at 95°C. Detection of CB~2~R and CB~1~R were performed through western blotting, as described above.

Single Cell Calcium Imaging (SCCI)
----------------------------------

To determine the functional neuronal differentiation of SVZ cells, the variations of intracellular calcium concentration (\[Ca^2+^\]~i~) in single cells following stimulation with 50 mM KCl and 100 mM histamine (Sigma--Aldrich) were analyzed as previously described for SVZ cells ([@B2]). KCl depolarization causes an increase in \[Ca^2+^\]~i~ in neurons, whereas stimulation with histamine leads to an increase in \[Ca^2+^\]~i~ in stem/progenitor cells ([@B2]; [@B73]). For SCCI analysis SVZ cultures plated in PDL-coated glass bottom cell culture dishes (Nest, NJ, United States) and grown for 7 days were loaded for 45 min with 5 μM Fura-2/AM (Invitrogen) and 0.02% pluronic acid F-127 (Invitrogen) in Krebs solution (132 mM NaCl, 4 mM KCl, 1.4 mM MgCl~2~, 1 mM CaCl~2~, 6 mM glucose, 10 mM HEPES, pH 7.4), in an incubator with 5% CO~2~ and 95% atmospheric air at 37°C. After a 5 min postloading period at RT in Krebs solution without Fura-2/AM and pluronic acid, to obtain a complete hydrolysis of the probe, the dish was mounted on an inverted microscope with epifluorescent optics (Axiovert 135TV, Zeiss) equipped with a xenon lamp and band-pass filters of 340 and 380 nm wavelengths. Cells were continuously perfused with Krebs solution and stimulated at defined periods of time by applying high-potassium Krebs solution (containing 50 mM KCl, isosmotic substitution with NaCl) and 100 μM histamine (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). Throughout the experiments, the cells were continuously superfused at 1.5 mL/min with physiological solution. KCl and histamine were applied focally through a drug filled micropipette placed under visual guidance. Image pairs obtained every 200 ms by exciting the preparations at 340 and 380 nm were taken to obtain ratio images. Excitation wavelengths were changed through a high-speed wavelength switcher, Lambda DG-4 (Sutter Instrument, Novato, CA, United States), and the emission wavelength was set to 510 nm. Image data was recorded with a cooled CCD camera (Photometrics CoolSNAP fx) and processed and analyzed using the software MetaFluor (Universal Imaging, West Chester, PA, United States). Regions of interest were defined manually over the cell profile. KCl and histamine peaks given by the normalized ratios of fluorescence at 340/380 nm, at the proper time periods, were used to calculate the ratios of the responses.

Microscopy
----------

Fluorescence images were recorded using an LSM 880 confocal microscope or an Axiovert 200 inverted widefield fluorescence microscope (both from Carl Zeiss Inc., Göttingen, Germany), with a 40x objective. Images were recorded using the softwares ZEN 2.1 (black edition) or AxioVision 4 (both from Carl Zeiss Inc.).

Statistical Analysis
--------------------

In all experiments, measurements were performed at the border of SVZ and DG neurospheres, where migrating cells form a pseudo-monolayer of cells. In every independent experiment, which corresponds to one independent neurosphere culture from one litter, each condition was measured in three different coverslips. Percentages of BrdU, BrdU/NeuN, NeuN, DCX and DCX/NeuN immunoreactive cells were calculated from cell counts of five independent microscopic fields in each triplicated coverslip (representing *n* = 1) with a 40x objective (∼200--400 cells per field). For quantification of neuritogenesis neurites were manually traced using NeuronJ v1.4.3, a plugin from ImageJ v1.46r (10 random images were captured per glass coverslip, in triplicates), measuring the total neurite length, the maximal neurite length, as well as the number of primary dendrites and branch points. An average of at least 10 neurons were acquired per glass coverslip for each experiment. All experiments were analyzed in a double-blind fashion and part of data was normalized to each corresponding control.

For SCCI experiments, the percentages of neuronal-like responding cells (with a Hist/KCl ratio below 0.8) and of immature-like responding cells (with a Hist/KCl ratio between 1 and 1.3) were calculated on the basis of one microscopic field per glass coverslip, containing approximately 100 cells, in a total of 3--4 independent cultures where each condition are duplicate.

Data are expressed as mean ± standard error of the mean (SEM). Statistical significance was determined using one-way analysis of variance followed by Sidak's or Dunnett's-multiple comparison test, with *p* \< 0.05 considered to represent statistical significance.

Results
=======

Neurosphere Culture Characterization: SVZ and DG Cultures Exhibit Type 1 and Type 2 Cannabinoid Receptors
---------------------------------------------------------------------------------------------------------

Using neurospheres as a method to study postnatal neurogenesis it was possible to observe that SVZ neurospheres are composed by stem/progenitor cells since they are formed by undifferentiated cells that express Sox2 (transcription factor important to maintain self-renewal) and Nestin (intermediate filament protein expressed by neuronal precursor cells) and, incorporate BrdU (**Figure [1A](#F1){ref-type="fig"}**). Importantly plating the neurospheres in differentiative conditions for 7 days (DIV 7) is sufficient to induce neuronal differentiation since a number of SVZ-derived cells express neuronal immature markers, such as doublecortin (DCX) and βIII tubulin and, also a marker for mature neurons, such as NeuN (**Figure [1C](#F1){ref-type="fig"}**). Furthermore, immunolabeling for the vesicular GABA transporter (VGAT, marker for GABAergic neurons) and the tyrosine hydroxylase (TH, marker for dopaminergic neurons) showed that SVZ-derived neurons express these proteins at DIV 7 (**Figures [1E,F](#F1){ref-type="fig"}**), which is in accordance with the fact that the two major phenotypes of SVZ-derived neurons are GABAergic and dopaminergic neurons. Similarly to SVZ cultures, DG neurospheres are also composed by undifferentiated cells expressing the stem/progenitor cell markers Sox2 and Nestin and with the ability to incorporate BrdU (**Figure [1B](#F1){ref-type="fig"}**). We have also observed that some DG-derived cells after 7 days in differentiative conditions (DIV 7) also express the immature markers DCX and βIII tubulin and the mature marker NeuN (**Figure [1D](#F1){ref-type="fig"}**). Additionally, DG-derived neurons at DIV 7 were found to express VGAT and vesicular glutamate transporter (VGlut1, marker for glutamatergic neurons), which reflects the two major phenotypes of DG-derived neurons, i.e., GABAergic and glutamatergic neurons (**Figures [1G,H](#F1){ref-type="fig"}**). Importantly, the expression of CB~1~R and CB~2~R in SVZ- and DG-derived cells was observed by immunocytochemistry and by western blotting (**Figures [1I](#F1){ref-type="fig"}--[K](#F1){ref-type="fig"}**). In fact, CB~1~R and CB~2~R expression was found in both DIV 1 and DIV 7 SVZ and DG cells as well as in adult tissue (**Figure [1K](#F1){ref-type="fig"}**). In particular, a band for CB~1~R was found in the predicted molecular weight (52 kDa) and other bands at higher molecular weights (between 52 and ∼70 kDa) were also found, which probably correspond to glycosylated forms of the receptor ([@B69]; [@B10]). Similarly, a band for CB~2~R was found at the predicted molecular weight (∼35 kDa) and other at ∼60 kDa which may also represent a glycosylated form ([@B34]; [@B10]).

![Characterization of SVZ and DG neurosphere cultures: neurospheres are composed by stem/progenitor cells and cells derived from neurosphere cultures undergo cell differentiation and express neuronal mature markers and both CB~1~R and CB~2~R. **(A,B)** Representative confocal digital images of a SVZ neurosphere **(A)** and a DG neurosphere **(B)** depicting Sox2 (red), BrdU (green), Nestin (white) and Hoechst 33342 (blue) immunoreactivity in 3 transverse planes (top, a/b1; middle, a/b2; bottom, a/b3). **(C--H)** Representative confocal digital images of SVZ cells **(C,E,F)** and DG cells **(D,G,H)** after 7 days of differentiation depicting immunoreactivity for immature and mature markers \[DCX (green), NeuN (red), βIII tubulin (white) and Hoechst 33342 (blue)\] **(C,D)** and for phenotypical markers \[TH (red), VGlut (red), VGAT (green), and Hoechst 33342 (blue)\] **(E--H)**. **(I,J)** Representative confocal digital images of SVZ cells **(I)** and DG cells **(J)** after 7 days of differentiation depicting CB~1~R (green), CB~2~R (red) and Hoechst 33342 (blue) immunoreactivity. **(K)** Detection of CB~1~R (molecular weight between 52 and ∼70 kDa) and CB~2~R (molecular weight of ∼35 and ∼60 kDa) by Western blotting in SVZ and DG cultures. For each immunoblot presented lane 1 corresponds to SVZ/DG proliferating cells (SVZ/DG DIV 1), lane 2 to SVZ/DG differentiated cells (SVZ/DG DIV 7) and lane 3 to SVZ/DG extracts from adult Sprague-Dawley rats (SVZ/DG A). Scale bars = 50 μm.](fphar-08-00516-g001){#F1}

CB~1~R Activation Stimulates SVZ Cell Proliferation
---------------------------------------------------

To determine if cannabinoid receptor activation modulates SVZ cell proliferation, increasing concentrations (100 nM, 300 nM, 1 μM) of selective CB~1~R (ACEA) and CB~2~R (HU-308) agonists and, non-selective CB~1~R and CB~2~R receptor agonist (WIN55,212-2) were applied on SVZ cells in SFM devoid of growth factors for 24 h. BrdU, a thymidine nucleotide analog, was added during the last 4 h of culture to label cells that went through S-phase. After fixation, incorporated BrdU was immunolabeled and positive nuclei were counted (**Figure [2A](#F2){ref-type="fig"}**). It was observed a significant increase in the number of BrdU-positive cells when cultures were incubated with 1 μM of the CB~1~R selective agonist ACEA, while 100 or 300 nM did not promote cell proliferation (control: 4.04 ± 0.18%; ACEA 1 μM: 5.67 ± 0.56%; *n* = 3, *p* \< 0.05) (**Figures [2B,C](#F2){ref-type="fig"}**). No significant changes were observed in the number of BrdU-immunopositive nuclei obtained in cultures incubated with all the aforementioned concentrations of either the CB~2~R selective agonist HU-308 (**Figures [2D,E](#F2){ref-type="fig"}**) or the non-selective CB~1~R and CB~2~R agonist WIN55,212-2 compared with control cultures (**Figures [2F,G](#F2){ref-type="fig"}**). Therefore, concentrations of 1 μM were chosen based on the concentration-response curve.

![CB~1~R selective activation stimulates SVZ cell proliferation. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 6 SVZ neurospheres were plated for 24 h and at Day 7 cells were exposed to pharmacological treatments for further 24 h (Day 8). **(B,D,F)** Bar graphs depict the number of BrdU-positive cells expressed as percentage of total cells *per* culture. Data are expressed as mean ± SEM. *n* = 2--5. ^∗^*p* \< 0.05 using Dunnett's multiple comparison test. **(C,E,G)** Representative fluorescent digital images of cells immunopositive for BrdU (green for **C,E**; red for **G**) and Hoechst 33342 staining (blue nuclei) (in control cultures and in cultures exposed to ACEA, HU-308 and WIN55,212-2 at the indicated concentrations. Scale bars = 50 μm.](fphar-08-00516-g002){#F2}

We then investigated the interaction between CB~1~R and CB~2~R by combining selective activation of both CB~1~R and CB~2~R agonists. As previously described, it was detected a significant increase in the number of BrdU-positive cells when cultures were incubated with the CB~1~R selective agonist ACEA (control: 100.01 ± 0.15%; ACEA 1 μM: 136.50 ± 5.15%; *n* = 11, *p* \< 0.001) compared with control cultures (**Figures [3A,B](#F3){ref-type="fig"}**). Concomitantly, no significant changes were obtained in cultures incubated with the CB~2~R selective agonist HU-308. Surprisingly when both CB~1~R and CB~2~R selective agonists were co-incubated the increase in cell proliferation mediated by CB~1~R activation was inhibited and therefore, had an effect similar to the observed by incubating with the non-selective CB~1~R and CB~2~R agonist WIN55,212 (**Figures [3A,B](#F3){ref-type="fig"}**). This suggests a role for CB~2~R in modulating the stimulatory effect promoted by CB~1~R on SVZ cell proliferation. To further elucidate the role of this CB~1~R-CB~2~R crosstalk on SVZ cell proliferation, cells were co-incubated with selective CB~1~R and CB~2~R selective antagonists (AM251 and AM630, respectively). The effect promoted by CB~1~R selective activation was blocked either in the presence of the CB~1~R selective antagonist AM251 (ACEA 1 μM + AM251 1 μM: 71.91 ± 12.49%; *n* = 3, *p* \< 0.001) or in the presence of the CB~2~R selective antagonist AM630 (ACEA 1 μM + AM630 1 μM: 99.36 ± 7.76%; *n* = 5, *p* \< 0.05) (**Figure [3C](#F3){ref-type="fig"}**), suggesting a putative interaction between CB~1~R and CB~2~R. Moreover, cells were further co-incubated with both CB~1~R and CB~2~R selective agonists (ACEA + HU-308) while being also incubated with either a CB~1~R or a CB~2~R antagonist, the data obtained being summarized in **Figure [3D](#F3){ref-type="fig"}**. When both selective agonists were present (ACEA + HU-308) and also in the presence of the CB~2~R selective antagonist, AM630, the effect promoted by ACEA alone on SVZ cell proliferation was rescued (ACEA 1 μM: 136.50 ± 5.15%; ACEA 1 μM+HU-308 1 μM + AM630 1 μM: 138.10 ± 4.77%; *n* = 5, *p* \< 0.05). Incubation with the CB~1~R selective antagonist, AM251, prior to co-exposure with both selective agonists (ACEA + HU-308) had no effect. Moreover, when cells were co-incubated with both CB~1~R and CB~2~R selective agonists and antagonists no significant changes were observed in the number of BrdU-positive cells (control: 100.00 ± 0.05%; ACEA 1 μM + HU-308 1 μM + AM251 1 μM + AM630 1 μM: 92.40 ± 18.09%; *n* = 3) (**Figure [3E](#F3){ref-type="fig"}**). We also did not observe any significant alterations when incubating cultures with both selective antagonists alone (**Figures [3C](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}**).

![CB~1~R-mediated increase in SVZ cell proliferation is changed by modulation of CB~2~R. **(A,C--E)** Bar graphs depict the number of BrdU-positive cells. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 3--11. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, using Sidak's multiple comparison test. **(B)** Representative fluorescent digital images of cells immunopositive for BrdU (green) and Hoechst 33342 staining (bluenuclei). Scale bar = 50 μm.](fphar-08-00516-g003){#F3}

Taken together, the above results indicate that the effect observed on SVZ cell proliferation is via CB~1~R and that it is markedly affected while perturbing the degree of activation of CB~2~R. Overactivation of CB~2~R by exogenous agonists hampers the action of CB~1~R, but full blockade of CB~2~R in the absence of exogenous CB~2~R agonist also prevents the influence of CB~1~R upon SVZ cell proliferation.

CB~1~R and CB~2~R Activation Induces SVZ Neuronal Differentiation
-----------------------------------------------------------------

To disclose whether cannabinoid receptor activation affects SVZ neuronal differentiation, SVZ cells were treated with increasing concentrations (100 nM, 300 nM, 1 μM) of selective CB~1~R (ACEA) and CB~2~R agonists (HU-308) and non-selective CB~1~R and CB~2~R agonist (WIN55,212-2) for 7 days in SFM without growth factor (**Figure [4A](#F4){ref-type="fig"}**). A significant increase in the number of NeuN-positive cells was observed when SVZ cultures were incubated with ACEA 1 μM but not with 100 or 300 nM, (control: 1.96 ± 0.14%; ACEA 1 μM: 3.72 ± 0.40%; *n* = 3--4, *p* \< 0.05) (**Figures [4B,C](#F4){ref-type="fig"}**). When incubating SVZ cultures with HU-308, the CB~2~R selective agonist, we observed a significant increase in the number of NeuN-positive cells in all tested concentrations \[control: 1.96 ± 0.14%; HU-308: 3.52 ± 0.27% (100 nM), 3.28 ± 0.38% (300 nM), 3.75 ± 0.32% (1 μM); *n* = 3--4, *p* \< 0.05 and *p* \< 0.01\] (**Figures [4D,E](#F4){ref-type="fig"}**). Moreover, it was observed a marked increase in the number of NeuN-immunopositive nuclei when cells were incubated with increasing concentrations of WIN55,212-2, which reached statistical significance for concentrations ≥300 nM \[control: 2.02 ± 0.28%; WIN55,212-2: 4.17 ± 1.13% (100 nM), 4.37 ± 1.23% (300 nM), 3.83 ± 0.47% (1 μM); *n* = 5--12, *p* \< 0.05) (**Figures [4F,G](#F4){ref-type="fig"}**\]. As with cell proliferation, 1 μM was the concentration selected for the following experiments. Interestingly, when we assessed whether selective or non-selective cannabinoid receptor activation would have an impact in the number of immature neurons, we observed a significant and robust increase in the number of DCX-positive cells with all receptor agonists used (control: 26.55 ± 2.12%; ACEA 1 μM: 51.43 ± 1.06%; HU-308 1 μM: 50.57 ± 2.75%; WIN55,212-2 1 μM: 49.30 ± 5.56%; *n* = 3, *p* \< 0.01 and *p* \< 0.001) (**Figures [4H,I](#F4){ref-type="fig"}**). To further support the role of cannabinoids in SVZ neuronal differentiation, we used a BrdU pulse for the first 24 h of treatments (CB~1~R and CB~2~R selective and non-selective activation) followed by a chase of 6 days (without BrdU) in the absence (control) or in the presence of the drug treatments (**Figure [4A](#F4){ref-type="fig"}**). We observed a 2.5-fold increase in the number of BrdU/NeuN-positive cells in all treated conditions (control: 5.97 ± 0.95%; ACEA 1 μM: 15.70 ± 1.38%; HU-308 1 μM: 15.40 ± 0.87%; WIN55,212-2 1 μM: 16.10 ± 0.49%; *n* = 4; *p* \< 0.001), indicating that cannabinoid treatment is interfering in the early stages of SVZ neuronal differentiation, committing progenitors toward a neuronal fate (**Figures [4J,K](#F4){ref-type="fig"}**).

![Selective and non-selective CBR activation induces SVZ neuronal differentiation. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 6 SVZ neurospheres were plated for 24 h and at Day 7 cells were exposed to pharmacological treatments for further 7 days (Day 14); for a subset of experiments BrdU was added for 24 h at Day 7. **(B,D,F,H,J)** Bar graphs depict the number of NeuN-positive cells expressed as percentage of total cells **(B,D,F)**; of DCX-positive cells expressed as percentage of total cells **(H)** and of BrdU/NeuN-positive cells expressed as percentage of total NeuN-positive cells **(J)** *per* culture. Data are expressed as mean ± SEM. *n* = 3--12. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001 using Dunnett's multiple comparison test. **(C--K)** Representative fluorescent digital images of NeuN+ (red) cells **(C--G)**; DCX+ (green), NeuN+ (red) cells **(I)**; BrdU+ (green), NeuN+ (red) cells **(K)**. Hoechst 33342 staining in blue, arrowheads indicate BrdU/NeuN-positive cells. Scale bars = 50 μm.](fphar-08-00516-g004){#F4}

To discriminate between the relative role of CB~1~R and CB~2~R upon neuronal differentiation, selective agonists for CB~1~R (ACEA, 1 μM) and for CB~2~R (HU-308, 1 μM) were used. Treatment of SVZ cells with either ACEA 1 μM or with HU-308 1 μM induced a significant (*p* \< 0.001, *n* = 11--14) increase in the number of NeuN-positive cells (control: 99.99 ± 0.03%; ACEA 1 μM: 157.10 ± 8.50%; HU-308 1 μM: 143.00 ± 7.62%) (**Figures [5A,B](#F5){ref-type="fig"}**). The facilitatory effect upon neuronal differentiation was still evident when both agonists were added together (ACEA 1 μM + HU-308 1 μM: 135.20 ± 14.23%), but remarkably, the effect of both agonists was not additive, with a similar effect comparing with the non-selective CB~1~R and CB~2~R WIN55,212-2 (**Figures [5A,B](#F5){ref-type="fig"}**). The effect caused by CB~1~R selective activation was blocked either in the presence of the CB~1~R selective antagonist AM251 (ACEA 1 μM + AM251 1 μM: 94.18 ± 6.17%; *n* = 5--14, *p* \< 0.001) or in the presence of the CB~2~R selective antagonist AM630 (ACEA 1 μM + AM630 1 μM: 91.74 ± 11.10%; *n* = 5, *p* \< 0.001) (**Figure [5C](#F5){ref-type="fig"}**). Similarly, the effect caused by CB~2~R activation was blocked either in the presence of the CB~1~R selective antagonist AM251 (HU-308 1μM + AM251 1 μM: 105.20 ± 9.02%; *n* = 5--15, *p* \< 0.01) or in the presence of the CB~2~R selective antagonist AM630 (HU-308 1 μM + AM630 1 μM: 105.20 ± 12.48%; *n* = 5, *p* \< 0.01) (**Figure [5D](#F5){ref-type="fig"}**). This crossed-antagonism strongly suggests the existence of a CB~1~R-CB~2~R interaction to regulate SVZ neuronal differentiation. To further confirm the need of an interaction between CB~1~R and CB~2~R to modulate SVZ neuronal differentiation, co-incubation of both selective agonists and antagonists was performed, the results obtained being depicted in **Figures [5E,F](#F5){ref-type="fig"}**. Incubation of the CB~1~R selective antagonist, AM251, together with both selective receptor agonists (ACEA + HU-308) induced no significant changes in the number of NeuN-positive cells when compared to control conditions (control: 100.02 ± 0.67%; ACEA 1 μM + HU-308 1 μM + AM251 1 μM: 117.40 ± 8.13%; *n* = 3--12) (**Figure [5E](#F5){ref-type="fig"}**). Interestingly, incubation of the CB~2~R selective antagonist, AM630, with both selective agonists allowed an increase in the number of NeuN-positive cells (ACEA 1 μM + HU-308 1 μM + AM630 1 μM: 151.10 ± 10.47%; *n* = 6, *p* \< 0.05) (**Figure [5E](#F5){ref-type="fig"}**), indicating that the influence of CB~1~R is preponderant over CB~2~R with respect to the modulation of SVZ neuronal differentiation. As expected, the effect promoted by both selective agonists, when added together, was abolished in the presence of both receptor antagonists (**Figure [5F](#F5){ref-type="fig"}**) (ACEA 1 μM + HU-308 1 μM + AM251 1 μM + AM630 1 μM: 103.50 ± 7.91%; *n* = 3--12). Additionally, no significant alterations were found when incubating cultures with both selective antagonists alone (**Figures [5C](#F5){ref-type="fig"}--[F](#F5){ref-type="fig"}**). Interestingly, the effect promoted by non-selective activation of CB~1~R and CB~2~R with WIN55,212-2 on SVZ neuronal differentiation was blocked when cells were co-incubated with the CB~1~R selective antagonist AM251 (WIN55,212-2 1 μM + AM251 1 μM: 89.23 ± 9.60%) (**Figure [5G](#F5){ref-type="fig"}**) or with the CB~2~R selective antagonist AM630 (WIN55,212-2 1 μM + AM630 1 μM: 91.43 ± 16.07%) (**Figure [5H](#F5){ref-type="fig"}**), showing that the effect of WIN 55,212-2 on SVZ cell proliferation is dependent on both CB~1~R and CB~2~R.

![CB~1~R and CB~2~R tightly regulate SVZ neuronal differentiation. **(A,C--H)** Bar graphs depict the number of NeuN-positive cells. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 3--15. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, using Sidak's multiple comparison test. **(B)** Representative fluorescent digital images of cells immunopositive for NeuN (red) and Hoechst 33342 staining (blue). Scale bar = 50 μm.](fphar-08-00516-g005){#F5}

In order to functionally evaluate neuronal differentiation of SVZ cells we used SCCI, as previously described ([@B73]). Briefly, variations of \[Ca^2+^\]~i~ at single cell level upon KCl and histamine (Hist) stimulations were measured and Hist/KCl ratios were calculated, therefore reflecting the phenotype of the analyzed cells. Ratios below 0.8 are characteristic of SVZ-derived neuronal-like cells whereas ratios between 1 and 1.3 are characteristic of SVZ-derived immature cells ([@B2]). Quantification of the percentage of cells displaying a Hist/KCl ratio below 0.8 showed a concentration-dependent increase in the % of neuronal-like cells with the CB~1~R selective agonist ACEA \[control: 10.21 ± 1.38%; ACEA: 15.83 ± 7.33% (100 nM), 22.67 ± 2.83% (300 nM), 29.75 ± 5.26% (1 μM); *n* = 3--4, *p* \< 0.05\], the CB~2~R selective agonist HU-308 \[control: 10.21 ± 1.38%; HU-308: 34.50 ± 3.75% (100 nM), 23.50 ± 6.53% (300 nM), 33.50 ± 5.86 (1 μM); *n* = 3--4, *p* \< 0.05\] and with the CB~1~R and CB~2~R non-selective agonist WIN55,212-2 \[control: 10.21 ± 1.38%; WIN55,212-2: 20.17 ± 5.05% (100 nM), 23.67 ± 4.88% (300 nM), 32.05 ± 4.93% (1 μM); *n* = 3--4, *p* \< 0.05\] (**Figures [6A,B](#F6){ref-type="fig"}**). Furthermore, selective activation of both receptors (ACEA + HU-308) also promoted a significant increase in the % of neuronal-like cells (ACEA 1 μM + HU-308 1 μM: 36.67 ± 5.40%; *n* = 3, *p* \< 0.001) (**Figures [6A,B](#F6){ref-type="fig"}**). In fact, a three-fold increase in the number of neuronal-like cells resulting from incubation of these cannabinoids receptor agonists at concentrations of 1 μM was observed, indicating a robust cannabinoid-mediated augmentation of neuronal differentiation. Moreover, CB~1~R and/or CB~2~R selective and non-selective activation were also found to promote a significant decrease in the % of immature-like cells (ratio Hist/KCl 1--1.3) at 1 μM concentration (control: 33.80 ± 5.06%; ACEA 1 μM: 15.25 ± 3.19%; HU-308 1 μM: 8.87 ± 3.16%; WIN55,212-2 1 μM: 14.50 ± 5.65%; ACEA 1 μM+HU-308 1 μM: 10.50 ± 3.68%; *n* = 3--4, *p* \< 0.05 and *p* \< 0.01) (**Figures [6A,C](#F6){ref-type="fig"}**). While control cultures displayed a predominant immature-like profile, characterized by an increase in \[Ca^2+^\]~i~ in response to histamine but a small response or no response to KCl stimulation, the majority of ACEA-, HU-308-, WIN55,212-2-treated SVZ cultures displayed an increase in \[Ca^2+^\]~i~ in response to KCl but not to histamine stimulation which is consistent with a neuronal-like profile (**Figure [6D](#F6){ref-type="fig"}** and **Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**).

![Selective and non-selective CBR activation promotes functional SVZ neuronal differentiation. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 6 SVZ neurospheres were plated for 24 h and at Day 7 cells were exposed to pharmacological treatments for further 7 days (Day 14). **(B,C)** Bar graphs depict the number of neuronal-like responding cells **(B)** and of immature-like responding cells **(C)** expressed as percentages of total cells analyzed by SCCI. Data are expressed as mean ± SEM. *n* = 3--4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 using Dunnett's multiple comparison test. **(D)** Representative SCCI profiles of response of 20 cells in control and ACEA, HU-308, WIN55,212-2, ACEA + HU-308 treated cultures.](fphar-08-00516-g006){#F6}

Finally, in agreement with the observed proneurogenic action of cannabinoids, we investigated whether our treatments triggered neuronal morphological changes, consistent with neuronal maturation, by looking at neurite outgrowth and branching processes of neurons stained for βIII tubulin (**Figures [7A,B](#F7){ref-type="fig"}**). When comparing to control neurons (**Figure [7C](#F7){ref-type="fig"}**), incubation of SVZ cultures with ACEA, HU-308 and WIN55,212-2 induced a significant increase in the total length of neurites per neuronal cell (control: 100.0 ± 0.0%; ACEA 1 μM: 124.2 ± 7.60%; HU-308 1 μM: 136.7 ± 6.94%; WIN55,212-2 1 μM: 142.4 ± 11.13%; *n* = 4--9, *p* \< 0.05, *p* \< 0.01 and *p* \< 0.001) (**Figure [7D](#F7){ref-type="fig"}**) and in the length of the maximal neurite (control: 100.0 ± 0.0%; ACEA 1 μM: 113.5 ± 8.66%; HU-308 1 μM: 124.0 ± 5.48%; WIN55,212-2 1 μM: 137.1 ± 5.47%; *n* = 4--9, *p* \< 0.01 and *p* \< 0.001) (**Figure [7F](#F7){ref-type="fig"}**). Furthermore, cannabinoid receptor agonists treatments promoted a marked increase in the number of branch points per cell when compared to control cultures (control: 100.0 ± 0.0%; ACEA 1 μM: 145.3 ± 6.32%; HU-308 1 μM: 168.1 ± 21.26%; WIN55,212-2 1 μM: 161.2 ± 7.22%; *n* = 4--9, *p* \< 0.01 and *p* \< 0.001) (**Figure [7G](#F7){ref-type="fig"}**) while not perturbing the number of primary neurites (**Figure [7E](#F7){ref-type="fig"}**).

![CB~1~R and CB~2~R activation induce neuronal maturation of SVZ cultures. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 6 SVZ neurospheres were dissociated and plated for 24 h and at Day 7 cells were exposed to pharmacological treatments for further 3 days (Day 10). **(B)** Representative digital images of βIII tubulin (white) positive cells in control and ACEA, HU-308, WIN55,212-2 treated cultures. **(C)** Illustrative image representing the color-coded morphological parameters evaluated and respective table with absolute values of control SVZ cultures for each parameter. **(D--G)** Bar graphs depict total length **(D)**, number of primary **(E)**, maximal length **(F)**, and number of ramifications **(G)** of neurites per cell. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 4--9. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, using Sidak's multiple comparison test. Scale bar = 30 μm.](fphar-08-00516-g007){#F7}

CB~1~R-CB~2~R Interaction Modulates DG Cell Proliferation
---------------------------------------------------------

It was next investigated the effect of cannabinoid receptor activation on DG cell proliferation. For that purpose, DG cells were treated with increasing concentrations (100 nM, 300 nM, 1 μM) of CB~1~R and CB~2~R selective agonists and a non-selective CB~1~R and CB~2~R agonist for 24 h in SFM devoid of growth factors (**Figure [8A](#F8){ref-type="fig"}**). As shown in **Figures [8B](#F8){ref-type="fig"}--[E](#F8){ref-type="fig"}**, CB~1~R selective activation with ACEA or CB~2~R selective activation with HU-308 did not promote any changes in the number of BrdU-positive cells in any tested concentration when compared with control conditions. Non-selective receptor activation with WIN55,212-2 caused a concentration-dependent increase in BrdU-positive cells, though the effect only reached statistical significance at 1 μM (control: 8.72 ± 3.16%; WIN55,212-2 1 μM: 18.55 ± 2.50%; *n* = 3--5, *p* \< 0.05) (**Figures [8F,G](#F8){ref-type="fig"}**).

![Non-selective CBR activation promotes DG cell proliferation. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 12 DG neurospheres were plated for 24 h and at Day 13 cells were exposed to pharmacological treatments for further 24 h (Day 14). **(B,D,F)** Bar graphs depict the number of BrdU-positive cells expressed as percentage of total cells *per* culture. Data are expressed as mean ± SEM. *n* = 2--5. ^∗^*p* \< 0.05, using Dunnett's multiple comparison test. **(C,E,G)** Representative fluorescent digital images of cells immunopositive for BrdU (green for **C,E**; red for **G**) and Hoechst 33342 staining (blue). Scale bars = 50 μm.](fphar-08-00516-g008){#F8}

To assess the relative role of each cannabinoid receptor, DG cultures were co-incubated with the selective receptor antagonists and agonists. There were no significant changes when incubating cultures with only ACEA or HU-308 (control: 100.00 ± 0.03%; ACEA 1 μM: 109.00 ± 9.65%; HU-308 1 μM: 98.68 ± 4.34%; *n* = 15, *p \>* 0.05) (**Figures [9A,B](#F9){ref-type="fig"}**), when compared to control cultures, concomitant with the abovementioned results. However, when co-incubating cultures with both selective agonists for CB~1~R and CB~2~R (ACEA + HU-308) a surprisingly significant increase was observed in the number of BrdU-positive cells (ACEA 1 μM + HU-308 1 μM: 162.50 ± 18.83%; *n* = 10, *p* \< 0.001), similar to the effect observed when cells were incubated with the non-selective receptor agonist WIN55,212-2 (**Figures [9A,B](#F9){ref-type="fig"}**). These results suggest that both receptors have to be active to induce DG proliferation. Furthermore, it was observed that in the presence of the CB~1~R selective antagonist, AM251, the effect promoted by incubation with both selective receptor agonists was lost (ACEA 1 μM + HU-308 1 μM + AM251 1 μM: 77.95 ± 4.12%; *n* = 5, *p* \< 0.01) (**Figure [9C](#F9){ref-type="fig"}**), whereas co-incubation with the CB~2~R selective antagonist AM630 did not block the effect mediated by CB~1~R and CB~2~R co-activation (ACEA 1 μM + HU-308 1 μM + AM630 1 μM: 162.60 ± 18.44%; *n* = 5, *p* \< 0.05) (**Figure [9C](#F9){ref-type="fig"}**). These data suggest that CB~1~R has a leading role in modulating DG proliferation. As could be expected, the effect promoted by co-incubation with both CB~1~R and CB~2~R selective agonists was completely lost when both receptor antagonists were present together (ACEA 1 μM + HU-308 1 μM + AM251 1 μM + AM630 1 μM: 68.76 ± 10.05%; *n* = 5, *p* \< 0.01) (**Figure [9D](#F9){ref-type="fig"}**). Interestingly, when cultures were incubated with the CB~1~R and CB~2~R selective antagonists in the absence of agonists, a significant decrease on DG cell proliferation was observed (AM251 1 μM + AM630 1 μM: 60.15 ± 12.00%; *n* = 5, *p* \< 0.05) (**Figure [9D](#F9){ref-type="fig"}**), suggesting a pivotal influence of endocannabinoids upon DG cell proliferation; single incubation with each of the receptor antagonist had no substantial effect (**Figures [9C,D](#F9){ref-type="fig"}**). Moreover, the increase on DG cell proliferation promoted by WIN55,212-2 1 μM was blocked either when cells were co-incubated with the CB~1~R selective antagonist AM251 (WIN55,212-2 1 μM+AM251 1 μM: 90.93 ± 8.10%; *n* = 5--23, *p* \< 0.05) (**Figure [9E](#F9){ref-type="fig"}**) or with the CB~2~R selective antagonist AM630 (WIN55,212-2 1 μM + AM630 1 μM: 96.85 ± 10.86%; *n* = 5--23, *p* \< 0.05) (**Figure [9F](#F9){ref-type="fig"}**), suggesting a CB~1~R-CB~2~R crosstalk mechanism mediating DG cell proliferation.

![CB~1~R-CB~2~R interaction controls DG cell proliferation. **(A,C--F)** Bar graph depicts the number of BrdU-positive cells. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 5--23. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001, using Sidak's multiple comparison test. ns, non-significant. **(B)** Representative fluorescent digital images of cells immunopositive for BrdU (green) and Hoechst 33342 staining (blue). Scale bar = 50 μm.](fphar-08-00516-g009){#F9}

DG Neuronal Differentiation Is Tightly Controlled by Cannabinoid Receptor Activation
------------------------------------------------------------------------------------

To determine the effect of cannabinoid receptor activation on DG neuronal differentiation, DG cells were treated with increasing concentrations (100 nM, 300 nM, 1 μM) of CB~1~R and CB~2~R selective agonists and a non-selective CB~1~R and CB~2~R agonist in SFM devoid of growth factors for 7 days (**Figure [10A](#F10){ref-type="fig"}**). CB~1~R selective activation with ACEA promoted a concentration-dependent increase in the number of NeuN-positive cells, reaching statistical significance at the concentration of 1 μM (control: 2.18 ± 0.33%; ACEA 1 μM: 4.51 ± 0.47%; *n* = 3--6, *p* \< 0.05) (**Figures [10B,C](#F10){ref-type="fig"}**). Similarly, when cultures were incubated with CB~2~R selective agonist HU-308 the same concentration-dependent profile was observed (control: 2.43 ± 0.44%; HU-308 1 μM: 4.57 ± 0.46%; *n* = 3--6, *p* \< 0.05) (**Figures [10D,E](#F10){ref-type="fig"}**). An increase in the number of NeuN-positive cells was observed with all concentrations used for the non-selective receptor agonist WIN55,212-2, only reaching statistical significance at the concentration of 1 μM (control: 3.61 ± 0.58%; WIN55,212-2 1 μM: 7.03 ± 1.06%; *n* = 3--10, *p* \< 0.05) (**Figures [10F,G](#F10){ref-type="fig"}**). When assessing the overall influence of cannabinoid receptors on early stages of DG neuronal differentiation by selectively activating CB~1~R (ACEA 1 μM) or CB~2~R (HU-308 1 μM) or, by non-selective receptor activation (WIN55,212-2 1 μM) we observed an increase in the number of immature neurons characterized by a significant increase in the number of DCX-positive cells (control: 10.73 ± 0.19%; ACEA 1 μM: 17.34 ± 1.13%; HU-308 1 μM: 17.00 ± 0.84%; WIN55,212-2 1 μM: 16.94 ± 1.18%; *n* = 3, *p* \< 0.01) (**Figures [10H,I](#F10){ref-type="fig"}**), showing that activation of cannabinoid receptors functions as an early neurogenic propeller. Similarly to SVZ, we next investigated whether CB~1~R and CB~2~R activation could be committing DG early progenitors toward a neuronal fate. For that a BrdU pulse was done in the first 24 h of a 7-day treatment with ACEA, HU-308 and WIN55,212-2 (**Figure [10A](#F10){ref-type="fig"}**). We observed a substantial increase in the number of BrdU/NeuN-positive cells in all treated conditions (control: 11.55 ± 0.97%; ACEA 1 μM: 27.80 ± 1.69%; HU-308 1 μM: 23.99 ± 2.13%; WIN55,212-2 1 μM: 25.88 ± 4.76%; *n* = 3, *p* \< 0.05 and *p* \< 0.01) (**Figures [10J,K](#F10){ref-type="fig"}**), suggesting that CB~1~R and CB~2~R activation have an impact in the early stages of DG neuronal differentiation by inducing the commitment of early progenitors toward a neuronal fate.

![Selective and non-selective CBR activation induces DG neuronal differentiation. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 12 DG neurospheres were plated for 24 h and at Day 13 cells were exposed to pharmacological treatments for further 7 days (Day 20); for a subset of experiments BrdU was added for 24 h at Day 13. **(B,D,F,H,J)** Bar graphs depict the number of NeuN-positive cells expressed as percentage of total cells (B, D, F), of DCX-positive cells expressed as percentage of total cells **(H)** and of BrdU/NeuN-positive cells expressed as percentage of total NeuN-positive cells **(J)** *per* culture. Data are expressed as mean ± SEM. *n* = 3--10. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, using Dunnett's multiple comparison test. **(C--K)** Representative fluorescent digital images of NeuN+ (red) cells **(C--G)**; DCX+ (green), NeuN+ (red) cells **(I)**; BrdU+ (green), NeuN+ (red) cells **(K)**. Hoechst 33342 staining in blue, arrowheads indicate BrdU/NeuN-positive cells. Scale bars = 50 μm.](fphar-08-00516-g010){#F10}

To evaluate whether the effect upon DG neuronal differentiation involves CB~1~R or CB~2~R, DG cells were treated with ACEA (1 μM) or HU-308 (1 μM) or a combination of both. It was observed a significant increase in the number of NeuN-positive cells when cultures were exposed to either the CB~1~R or the CB~2~R selective agonists (control: 100.02 ± 0.04%; ACEA 1 μM: 154.10 ± 17.78%; HU-308 1 μM: 151.50 ± 10.61%; *n* = 14--16, *p* \< 0.01), as well as when both agonists were added together (ACEA 1 μM + HU-308 1 μM: 149.90 ± 18.81%; *n* = 7, *p* \< 0.05) with an effect similar to the observed with the non-selective CB~1~R and CB~2~R agonist WIN55,212-2 (**Figures [11A,B](#F11){ref-type="fig"}**). Furthermore, the effect caused by CB~1~R selective activation was blocked either in the presence of the CB~1~R selective antagonist AM251 (ACEA 1 μM + AM251 1 μM: 100.50 ± 14.17%; *n* = 6, *p* \< 0.01) or in the presence of the CB~2~R selective antagonist AM630 (ACEA 1 μM + AM630 1 μM: 79.42 ± 15.34%; *n* = 7, *p* \< 0.001) (**Figure [11C](#F11){ref-type="fig"}**). Similarly, the effect caused by CB~2~R activation was blocked either in the presence of the CB~1~R selective antagonist AM251 (HU-308 1 μM + AM251 1 μM: 70.36 ± 13.58%; *n* = 7, *p* \< 0.001) or in the presence of the CB~2~R selective antagonist AM630 (HU-308 1 μM + AM630 1 μM: 99.34 ± 22.89%; *n* = 6, *p* \< 0.01) (**Figure [11D](#F11){ref-type="fig"}**). The CB~1~R selective antagonist AM251 alone was able prevent the effect of both agonists added together (ACEA + HU-308) (control: 100.04 ± 2.05%; ACEA 1 μM+HU-308 1 μM + AM251 1 μM: 72.26 ± 10.39%; *n* = 3, *p* \< 0.05) (**Figure [11E](#F11){ref-type="fig"}**). Similarly, co-incubation with the CB~2~R selective antagonist AM630 blocked the effect mediated by CB~1~R and CB~2~R co-activation (ACEA 1 μM + HU-308 1 μM + AM630 1 μM: 98.35 ± 18.60%; *n* = 3) (**Figure [11E](#F11){ref-type="fig"}**). Additionally, when co-incubating with both selective antagonists, the effect promoted by both selective agonists was lost, compared to control cultures (control: 100.00 ± 0.43%; ACEA 1 μM + HU-308 1 μM + AM251 1 μM + AM630 1 μM: 68.36 ± 11.52%; *n* = 3, *p* \< 0.01) (**Figure [11F](#F11){ref-type="fig"}**). In any case did the incubation with the antagonists alone cause significant effects as compared with control (**Figure [11](#F11){ref-type="fig"}**). Moreover, the effect promoted by 1 μM WIN55,212-2 on DG neuronal differentiation was blocked in the presence of the CB~1~R selective antagonist AM251 (WIN55,212-2 1 μM + AM251 1 μM: 74.61 ± 7.74%; *n* = 6, *p* \< 0.01) (**Figure [11G](#F11){ref-type="fig"}**), as well as in the presence of the CB~2~R selective antagonist AM630 (WIN55,212-2 1 μM + AM630 1 μM: 117.20 ± 15.52%; *n* = 7, *p* \< 0.05) (**Figure [11H](#F11){ref-type="fig"}**). Taken together, the above results point toward an action CB~1~R and CB~2~R as modulators of DG neuronal differentiation and further suggest the existence of crosstalk between CB~1~R and CB~2~R to control postnatal neurogenesis.

![CB~1~R and CB~2~R crosstalk controls DG neuronal differentiation. **(A,C--H)** Bar graphs depict the number of NeuN-positive cells. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 3--16. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, using Sidak's multiple comparison test. **(B)** Representative fluorescent digital images of cells immunopositive for NeuN (red) and Hoechst 33342 staining (blue). Scale bar = 50 μm.](fphar-08-00516-g011){#F11}

To further study the cannabinoid-stimulatory effect on DG neurogenesis, we treated DG cultures with selective and non-selective CB~1~R and CB~2~R agonists and evaluated the effect on neurite outgrowth of βIII tubulin-positive cells (**Figures [12A,B](#F12){ref-type="fig"}**). When comparing to control cultures (**Figure [12C](#F12){ref-type="fig"}**), CB~1~R and CB~2~R activation with the selective and non-selective receptor agonists promoted a significant increase in the total neurite length per cell (control: 100.0 ± 0.0%; ACEA 1 μM: 154.5 ± 20.15%; HU-308 1 μM: 145.0 ± 8.45%; WIN55,212-2 1 μM: 128.7 ± 11.51%; *n* = 3--4; *p* \< 0.05 and *p* \< 0.01) (**Figure [12D](#F12){ref-type="fig"}**). Moreover, although no changes were detected regarding the number of primary neurites per neuron and the maximal neurite length (**Figures [12E,F](#F12){ref-type="fig"}**) it was observed a marked increase in the number of branch points per cell when compared to control cultures (control: 100.0 ± 0.0%; ACEA 1 μM: 141.7 ± 0.48%; HU-308 1 μM: 146.3 ± 16.70%; WIN55,212-2 1 μM: 155.7 ± 15.81%; *n* = 3--4; *p* \< 0.05 and *p* \< 0.01) (**Figure [12G](#F12){ref-type="fig"}**). These results suggest that cannabinoid receptors are important modulators of DG neuronal maturation process.

![Activation of CBR induce neuronal maturation of DG cultures. **(A)** Schematic representation of the experimental protocol. Day 0 represents the day of cultures; at Day 12 DG neurospheres were dissociated and plated for 24 h and at Day 13 cells were exposed to pharmacological treatments for further 2 days (Day 15). **(B)** Representative digital images of βIII tubulin (white) positive cells in control and ACEA, HU-308, WIN55,212-2 treated cultures. **(C)** Illustrative image representing the color-coded morphological parameters evaluated and respective table with absolute values of control DG cultures for each parameter. **(D--G)** Bar graphs depict total length **(D)**, number of primary **(E)**, maximal length **(F)** and number of ramifications **(G)** of neurites per cell. Values were normalized to the control mean for each experiment and are represented as mean ± SEM. Control was set to 100%. *n* = 3-4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, using Sidak's multiple comparison test. Scale bar = 30 μm.](fphar-08-00516-g012){#F12}

CB~1~ Receptors Co-immunoprecipitate with CB~2~ Receptors in SVZ and DG Cultures
--------------------------------------------------------------------------------

The overall crosstalk actions of CB~1~R and CB~2~R in SVZ and DG cultures hints at a possible physical interaction of these receptors. To test this hypothesis, we performed immunoprecipitation with an anti-CB~2~R receptor antibody in SVZ and DG cultures at DIV 1 and DIV 7 (molecular weight of ∼35 and 60 kDa). Subsequent immunoblot analyses of the composition of the immunoprecipitates showed a tenuous detection of CB~1~R at ∼52 and 60 kDa molecular weight in SVZ (**Figure [13A](#F13){ref-type="fig"}**) and DG (**Figure [13B](#F13){ref-type="fig"}**) cultures at both time points suggesting that CB~1~R and CB~2~R interact at the protein--protein physical level.

![Co-immunoprecipitation (co-IP) of CB~1~R and CB~2~R. Co-immunoprecipitation assay to determine the interaction between CB~1~R (molecular weight between 52 and ∼70 kDa) and CB~2~R (molecular weight of ∼35 and ∼60 kDa) in SVZ cultures **(A)** and in DG cultures **(B)** at both DIV 1 and DIV 7. NC, negative control (beads + sample without antibody); IP, sample bound to antibody-bead mixture; raw lysate, lysed SVZ and DG cultures; supernantant, sample not bound to antibody-bead mixture.](fphar-08-00516-g013){#F13}

Discussion
==========

A main finding herein reported for the first time is the crosstalk between cannabinoid CB~1~ and CB~2~ receptors in the control of proliferation and differentiation of SVZ- and DG-derived NSPC. It was observed that CB~1~R and CB~2~R co-activation had no additive effect when compared with the effect mediated by the receptor agonists alone. Importantly, selective activation of CB~1~R induced an increase in SVZ cell proliferation that was lost when CB~1~R and CB~2~R were co-activated. Surprisingly, regarding DG cell proliferation, the selective activation of CB~1~R or CB~2~R has no effect but co-incubation with both CB~1~R and CB~2~R agonists promoted an increase in proliferation similar to the observed with a CB~1~R and CB~2~R non-selective agonist, indicating the need of simultaneous activation of the two receptors to facilitate DG cell proliferation, in clear contrast with the SVZ cell proliferation, where the CB~1~R is the predominant receptor to control proliferation. A constant finding in both neurogenic niches and in the modulation of either proliferation or differentiation, is the cross-antagonism between CB~1~R and CB~2~R (**Table [3](#T3){ref-type="table"}**).

###### 

Summary table.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  *Treatments*                   SVZ cells                                           DG cells
  ------------------------------ --------------------------------------------------- ----------------------------------------------------------------
  **Cell proliferation**                                                             

  Non-selective CBR activation   **=**                                               **↑ ↑ ↑**

  CB~1~R activation              **↑ ↑ ↑**                                           **=**

  CB~2~R activation              **=**                                               **=**

  CB~1~R + CB~2~R activation     **=**                                               **↑ ↑ ↑**

  CB~1~R blockage                **--\]** CB~1~R effect                              **--\]** CB~1~R + CB~2~R effect

  CB~2~R blockage                **--\]** CB~1~R effect                              **--\]** CB~1~R + CB~2~R effect

  **Neuronal differentiation**                                                       

  Non-selective CBR activation   **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~1~R activation              **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~2~R activation              **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~1~R + CB~2~R activation     **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~1~R blockage                **--\]** Non-selective CBR effect\                  **--\]** Non-selective CBR effect\
                                 **--\]** CB~1~R/CB~2~R effect                       **--\]** CB~1~R/CB~2~R effect\
                                                                                     **--\]** CB~1~R + CB~2~R effect

  CB~2~R blockage                **--\]** Non-selective CBR effect\                  **--\]** Non-selective CBR effect**--\]** CB~1~R/CB~2~R effect
                                 **--\]** CB~1~R / CB~2~R effect\                    
                                 ![](fphar-08-00516-i001.jpg) CB~1~R+CB~2~R effect   

  **Neuronal maturation**                                                            

  Non-selective CBR activation   **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~1~R activation              **↑ ↑ ↑**                                           **↑ ↑ ↑**

  CB~2~R activation              **↑ ↑ ↑**                                           **↑ ↑ ↑**
  ---------------------------------------------------------------------------------------------------------------------------------------------------

↑ ↑ ↑

significant increase; = no significant effect; --\] effect blockage;

restored effect.

Firstly, we detected by western blotting and immunocytochemistry that cells derived from SVZ and DG rat neurospheres express CB~1~R and CB~2~R. This is in accordance with several authors which have shown that both CB~1~R and CB~2~R are expressed in these regions ([@B42]; [@B3]).

Interestingly we observed that HU-308 (CB~2~R selective agonist) and WIN55,212-2 (CB~1~R and CB~2~R non-selective agonist) treatments had no effect on SVZ cell proliferation. Nevertheless, selective CB~1~R activation with ACEA promoted a significant increase in cell proliferation of SVZ cultures, an effect that was lost when cultures were co-incubated together with CB~1~R or CB~2~R selective antagonists. Several reports showed that CB~1~R activation indeed promoted SVZ cell proliferation ([@B70]; [@B20]; [@B15]; [@B73]). Moreover, CB~1~R and CB~2~R activation was found to promote proliferation of primary murine cortical neurospheres ([@B66]) and of mouse NSPC via IL-1 signaling pathways ([@B31]). Others have also shown that CB~2~R activation could promote proliferation in embryonic cell lines, in SVZ neurosphere cultures and in the SVZ of young mice ([@B33]; [@B60]). However, in our experimental conditions, CB~2~R activation did not induce cell proliferation. Interestingly, the observed increase in SVZ cell proliferation mediated by CB~1~R selective activation was abolished in the presence of the CB~2~R selective agonist. In fact, this result may help to explain why treatment with the non-selective CB~1~R and CB~2~R agonist had no effect. Importantly, the effect promoted by activation of CB~1~R in cell proliferation was reestablished in SVZ cells incubated with the selective agonists for CB~1~R and CB~2~R that were pre-treated with the CB~2~R selective antagonist. These findings suggest a negative crosstalk between CB~1~R and CB~2~R.

Regarding SVZ neuronal differentiation, it was found to be significantly increased upon WIN55,212-2 treatment as well as with CB~1~R and/or CB~2~R selective activation. The effect promoted by WIN55,212-2 was lost when cultures were co-incubated with either CB~1~R or CB~2~R selective antagonists. Similarly, the effect mediated by CB~1~R or CB~2~R in SVZ neuronal differentiation was blocked in the presence of CB~1~R or CB~2~R antagonists. Selective and non-selective cannabinoid receptor activation was shown to stimulate SVZ neuronal differentiation not only by promoting an increase in the number of NeuN-positive cells but also by expanding the pool of immature neurons, i.e., by increasing the number of DCX-positive cells and by accelerating the differentiation of proliferating neuronal precursor cells, i.e., by increasing the number of BrdU/NeuN-positive cells. In fact, we showed by SCCI that CB~1~R and CB~2~R activation induces functional neuronal differentiation in SVZ cell cultures, reflected by a striking three-fold increase in the number of neuronal-like cells. Moreover, treatment with CB~1~R and/or CB~2~R agonists enhanced neuronal maturation by promoting a more pronounced arborization of newly formed neurons, being observed a higher number of ramifications and an increase in neurite length. Throughout literature, the existing data appears to be conflicting. In fact, the work done by [@B15] and [@B73] also shows that CB~1~R activation is important to promote neuronal differentiation. However, [@B4] and [@B32] showed that endocannabinoid treatment promoted astroglial and/or oligodendroglial differentiation rather than neuronal differentiation, while adult CB~1~R knockout resulted in a decrease in neural proliferation ([@B4]). Our data strongly suggests a pivotal two-part interaction between CB~1~R and CB~2~R in the regulation of SVZ proliferation and neuronal differentiation and maturation, highlighting the need to interpret results that involve the prevention of the activation of one receptor on the light of its impact upon the other receptor subtype, thus helping to understand some inconsistencies reported in the literature.

While SVZ neurogenesis might be particularly relevant in olfactory control as well as in the putative inhibition upon neurodegeneration ([@B16]), the role of cannabinoids on hippocampal neurogenesis has been intensively studied in an attempt to understand how endocannabinoids can shape learning and memory processes. Evidence so far observed show that the number of proliferating cells in the DG is reduced in CB~1~R- or CB~2~R-deficient mice and that CB~1~R and CB~2~R play major roles in NSPC proliferation, morphogenesis and differentiation ([@B59]; [@B54]; [@B30]). Therefore, we explored whether CB~1~R-CB~2~R crosstalk could have an impact on DG cell proliferation and neuronal differentiation. We observed that treatment with CB~1~R and CB~2~R non-selective agonist promoted an increase in DG cell proliferation and that this effect was lost when cultures were co-treated with the CB~1~R or CB~2~R selective antagonists. Surprisingly, no changes were observed when cultures were treated with CB~1~R or CB~2~R selective agonists alone. Remarkably, co-incubation of both selective CB~1~R and CB~2~R agonists resulted in a significant increase in DG cell proliferation. Together, these results strongly indicate the need of co-activation of both CB~1~R and CB~2~R to affect DG proliferation. The effect promoted by co-incubation with the CB~1~R and CB~2~R agonists was blocked in the presence of the CB~1~R antagonist, but not by the CB~2~R antagonist, suggesting that CB~1~R plays a major role in this process. The current available data about the effects promoted by CB~1~R or CB~2~R on DG cell proliferation is still quite controversial. In fact, some reports demonstrated that DG cell proliferation and survival was significantly impaired when using CB~1~R and CB~2~R knockout mice models ([@B4]; [@B59]) and that CB~1~R or CB~2~R activation *per se* promoted an increase in cell proliferation in the DG ([@B41]; [@B60]) or rescued the deleterious effect on NSPC proliferation promoted by ethanol ([@B64]). However, other studies showed that CB~1~R antagonism resulted in an enhanced DG cell proliferation ([@B39]; [@B71]). Our data is in accordance with [@B3] that observed that WIN55,212-2 treatment promoted an increase on DG cell proliferation and advances a step in the field by revealing a tight interaction between CB~1~R and CB~2~R in the regulation of this process.

Treatment with the CB~1~R and CB~2~R non-selective agonist also stimulated DG neuronal differentiation. Moreover, the same effect was observed when DG cells were treated with either CB~1~R or CB~2~R selective agonists. In the case of neuronal differentiation, data indicates that activation of only one or the two receptors was enough to trigger this effect. These results are in accordance with the work of [@B15] in which AEA enhances cell differentiation toward a neuronal lineage, via a CB~1~R-dependent mechanism. Furthermore, the work by [@B71] also showed that in the absence of CB~1~R, neuronal differentiation is reduced. Additionally, it was also showed that administration of a CB~2~R agonist promoted differentiation of human NSPC ([@B8]). In our experimental conditions, CB~1~R and/or CB~2~R activation induced DG neuronal differentiation, being observed both a marked increase in the number of immature neurons (DCX-positive cells) and a substantial increase in the number of progenitor cells labeled with BrdU that ultimately differentiated into NeuN-positive mature neurons (BrdU/NeuN-positive cells). Furthermore, treatment with CB~1~R and/or CB~2~R agonists promoted a potentiation of DG neuronal maturation processes, i.e., neurite length and branching. Importantly, the novelty of our data resides in the observation that the effect mediated by the CB~1~R selective agonist on neuronal differentiation was blocked with CB~1~R or CB~2~R antagonists and the same was observed regarding the effect promoted by the CB~2~R selective agonist. Likewise, WIN55,212-2 (CB~1~R and CB~2~R non-selective agonist)-mediated increase in DG neuronal differentiation was blocked in the presence of CB~1~R or CB~2~R selective antagonists. Hence, these data demonstrates that, though both receptors can independently affect DG neuronal differentiation, they do so in a close interaction so that, by blocking only one of them, the CB~1~R-CB~2~R-mediated effect is lost. This phenomenon of cross-antagonism has been considered a fingerprint of heteromerization, thus expression of CB~1~R-CB~2~R heteromers may explain how CB~1~R and CB~2~R control DG neuronal differentiation.

Hence, to address this issue, we performed co-IP experiments using DIV 1 and DIV 7 SVZ and DG cultures. The co-IP data suggest CB~1~R to be associated with CB~2~R, indicating the possible existence of CB~1~R-CB~2~R heteromers in our experimental conditions.

Divergent effects are observed throughout literature concerning the role of endocannabinoids on neurogenesis which may be partly explained from the use of different pharmacological approaches or differences in study design, animal species or gender used. From our study it becomes clear that the use of non-selective cannabinoid receptor ligands may account for the differences among studies. Furthermore, as observed by [@B42], treatment with SR141716A, a CB~1~R antagonist, promoted an increase in cell proliferation in the SVZ of CB~1~R-KO animals, showing that this effect is not dependent of CB~1~R. The age of the animal is also a determining factor. In fact, [@B1] have showed that chronic administration of WIN55,212-2 to rats during adulthood had no effect on the number of immature neurons in the DG; however, administration during adolescence decreased the number of immature neurons. Using the same compound, other group found that a low, continuous administration significantly increased neurogenesis in aged rats ([@B50]). Moreover, [@B3], through an *in vitro* approach, also showed that WIN55,212-2 promoted an increase in the number of neural progenitors and generation of neurospheres. These findings demonstrate that compound selectivity and the system that it is used on are extremely important factors when studying neurogenesis, and that regulation of this process may happen at a multidimensional level, which accounts for the complexity/variety of the system.

Overall, our results show that both proliferation and differentiation/maturation are being stimulated upon pharmacological cannabinoid receptor activation. In fact, cannabinoid receptors are important modulators of neurogenesis by acting at distinct neurogenic phases ([@B3]; [@B73]; [@B8]; [@B63]). Moreover, our results suggest that activation of CB~1~R and/or CB~2~R, although being important for cell proliferation, plays a preponderant role in stimulating neuronal differentiation and maturation processes in both SVZ and DG cells. Our data also shows that SVZ and DG neurogenic niches respond differently to the same pharmacological treatments. Particularly regarding cell proliferation, WIN55,212-2 treatment was found to promote DG cell proliferation but not SVZ cell proliferation, whereas CB~1~R selective activation with ACEA promoted SVZ cell proliferation and only co-activation of CB~1~R and CB~2~R induced DG cell proliferation (**Table [3](#T3){ref-type="table"}**). These differences can be to some extent due to the properties of each NSPC population and the heterogeneity within each NSPC pool ([@B36]). In fact, there are divergences between the two niche microenvironments regarding molecules regulating morphogenesis, rates of division and survival which may account for the observed differences ([@B17]; [@B11]).

Notably, part of the pharmacological differences could be explained by the existence of CB~1~R-CB~2~R heteromers. A heteromer receptor is, by definition, a macromolecular complex composed of at least two functional receptor units with biochemical properties that are demonstrably different from those of its individual receptors ([@B24]). BRET and PLA approaches have indeed shown that CB~1~R and CB~2~R co-localize in HEK-293T cells and SH-SY5Y neuroblastoma cells as well as puts into evidence the presence of CB~1~R-CB~2~R heteromers in a variety of rat brain regions (pineal gland, nucleus accumbens and globus pallidus) ([@B13]). Furthermore, in the same study, the authors observed a functional interdependence between CB~1~R and CB~2~R that varyingly modulated Akt/PKB signaling and neurite outgrowth. Moreover, an *in situ* assay showed the presence of CB~1~R-CB~2~R heteromers within basal ganglia output neurons in macaques ([@B68]). In the same way, it was already shown that CB~1~Rs and CB~2~Rs are expressed in rat SVZ and DG tissue and neurosphere-derived cells ([@B55]; [@B34]; [@B7]). Particularly, NSPC express a functional endocannabinoid system and are able to produce both AEA and 2-AG and, also, that are targeted by cannabinoids to promote neurosphere generation and NSPC proliferation ([@B3]; [@B59]). Similarly to the study of [@B13], our study also reveals a bidirectional cross-antagonism in which CB~1~R antagonists have the ability to block CB~2~R agonist-mediated effects on neurogenesis and vice-versa, a phenomenon that occurs in either SVZ- or DG-derived NSPC. Importantly, our study expands the evidence of the relevance of CB~1~-CB~2~ receptor crosstalk in neuronal differentiation and proliferation. It is likely that differences between the SVZ and DG niches may result from different expression of CB~1~R-CB~2~R heteromers that, eventually, translates into differences in the proliferation or differentiation rates of each niche cell population.

While much progress has been made in recent decades to understand the role of endocannabinoids on neurogenesis, our results provide a new perspective on how CB~1~R and CB~2~R might be modulating each other to control neurogenesis putatively through CB~1~R-CB~2~R heteromer complexes. One explanation for the mechanism behind this interaction may be that direct antagonism toward one receptor may be blocking the function of the entire heteromer. Also, similarly to the opioid receptor pharmacology, in which heteromerization between the μ-opioid receptor and δ-opioid receptor shows a "biased antagonism" ([@B52]), one receptor can be using the other as an antagonizing signal (or vice-versa) when both CB~1~R and CB~2~R are co-expressed in the same NSPC, having a significant impact on receptor signaling and, ultimately, in the regulation of neurogenesis. In other cases, both receptors may need to be co-activated in a concerted way so that correct signaling between them occurs. Indeed, this interdependent CB~1~R-CB~2~R modulation of neurogenesis may be occurring at distinct levels of action or at unique temporal time-windows resulting in different pivotal roles depending on the region NSPC are obtained, that is SVZ or DG, or on which neurogenic stage NSPC are in.

Taken together, our study demonstrates a clear CB~1~R-CB~2~R interaction that is responsible for a differential modulation of SVZ and DG neurogenic properties, such as proliferation, neuronal differentiation and maturation. Further studies are required to both define the importance of this crosstalk and elucidate the mechanisms involved, that may result either from protein--protein interaction (formation of heteromeric receptor complexes), mediated by G proteins, effectors, or second messengers. Certainly, future high-resolution imaging studies will be required to determine the dynamics of this receptor-receptor interaction within NSPC derived from both neurogenic niches and its contribution to proliferation and differentiation processes. For that reason, the designing of cannabinoid-based pharmacological tools that may prove promising must take into account the existence of this complex heteroreceptor crosstalk. Targeting cannabinoid receptors in a combined manner rather than each one individually may thus prove itself to be more efficient when designing therapeutical approaches to enhance neurogenesis.
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Temporal order of pharmacological treatments. Treatment of cultures with **(A)** only CB~1~R and CB~2~R agonists, **(B)** CB~1~R or CB~2~R antagonists and CB~1~R or CB~2~R agonists or **(C)** CB~1~R and/or CB~2~R antagonists and CB~1~R and/or CB~2~R agonists.
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Click here for additional data file.

###### 

Single cell calcium imaging (SCCI) timecourse and representative response patterns. Timecourse of SCCI experiments depicting the defined timepoints of stimulation with KCl and histamine (Hist) at 300 and 600 s, respectively. Representative \[Ca^2+^\]~i~ images of control, ACEA, HU-308, WIN55,212-2 and ACEA+HU-308 treated cultures at specific timepoints: baseline (120 s), KCl peak (300 s), KCl washout (480 s), Hist peak (600 s) and Hist washout (900 s); arrows indicate cells that display an increase in \[Ca^2+^\]~i~ in response to KCl but not to Hist stimulation representing neuronal-like cells.

###### 
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Click here for additional data file.

2-AG

:   2-arachidonoylglycerol

AEA

:   arachidonoylethanolamide

CBR

:   cannabinoid receptors

CB~1~R

:   cannabinoid receptors type 1

CB~2~R

:   cannabinoid receptors type 2

CNS

:   central nervous system

DG

:   dentate gyrus

EGF

:   epidermal growth factor

FGF-2

:   fibroblast growth factor-2

GPCRs

:   G protein-coupled receptors

NSPC

:   neural stem/progenitor cells

SVZ

:   subventricular zone

SGZ

:   subgranular zone
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